APASL 2013---The 23th Conference of the Asian Pacific Association for the Study of the Liver
Poster Presentation(Abstract NO 1131)
Hepatology International. 2013, 7(Suppl 1):s227.
Bang-Fu Wu1,2, Jiang-Ying Yang2,
Ya-Lin Zhang3, Yong Liu1, Hui-Hua Zhou3,
Xuan-Qin Wang1, Fang-Qin Li1, Chun-Qiong Hou3,
Xue-Song Li1, Xiang-Hua Huang1, Zheng-Sheng Xiao1,
Ming Yang1, Fu-Xin Lin3, Yan-Ping Fu3, Shuo
Zheng3, Wei Chen3, Yun Zhou2, Jun Yang2,
Xin-He Wan1, Hui Huang1
1.Gastroenterology and Hepatology Center, Southern Medical
University Renkang Hospital, Houjie Dongxi Road, No.88, Dongguan 523952, China
2 Guangzhou Pubang Bio-Immunological Tech
Research Institute, Kezhu Road, No.232-2, Room 205, Guangzhou Science City,
Luogang District, Guangzhou 510663, China
3 Gastroenterology and Hepatology Center, Tongji Medical
College Affiliated Dongguan Hospital, Huazhong University of Science and
Technology, Liaobu Southwest Road, No.171-175, Dongguan 523416, China
Background/Aims: To observe the clinical efficacy of anti-HBV-DC vaccine, the dendritic
cells originating from peripheral blood mononuclear cells(PBMC) sensitized by
HBsAg, in combination with thymosin-α1, in the inactive HBsAg carriers.
Methods:24 inactive HBsAg carriers were recruited in the trial
including 15 males and 9 females aged 18-57 years. PBMCs obtained from 50ml of
heparinized peripheral blood through density gradient centrifuge and adherence
method were proliferated under the induction by GM-CSF and IL-4, and sensitized
with the stock of hepatitis B vaccine containing 30µg HBsAg on day 5 and with
hepatitis B vaccine commercially available containing 20µg HBsAg on day 6.
anti-HBV-DC vaccine was harvested on day 7 and injected, half hypodermically
and half intravenously, to the patient once every two weeks for 12 practices
applications totally. Thymosin-α1 1.6mg was injected hypodermically twice a
week. Quantitative HBVM(TRFIA) and HBVDNA and hepatic functions were evaluated
at week 0, 4, 12, and 24.
Results: Mean of HBsAg decreased gradually along the time from week 4,
12 to 24, with significant difference compared with the values prior to
treatment. At week 4, 12 and 24, HBsAg negative conversion rate were
12.50%(3/24), 25.00%(6/24) and 37.50%(9/24) respectively.
The rate of adverse effect was 2.78% observed in reinfusion of anti-HBV-DC
vaccine.
Conclusions: anti-HBV-DC vaccine in combination with thymosin-α1 can be
considered as a safe approach with high efficacy for inactive HBsAg carriers,
which can decrease rapidly the HBsAg, and may eliminate the HBsAg for partial
inactive HBsAg carriers.
Author Keywords: Dendritic cells (DC);
Hepatitis B virus (HBV); Inactive HBsAg carriers; Vaccine
|
